Pariglasgene brecaparvovec is an adeno-associated virus serotype 8 (AAV8) based gene therapy designed to deliver a copy of the glucose-6-phosphatase (G6PC) gene with native human G6PC promoter and enhancer elements to hepatocytes, resulting in the production of normally functioning G6Pase.
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| GENGLYCOS Suspension for intravenous infusion | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Pariglasgene brecaparvovec is an active ingredient of these brands:
United States (US)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.